HA
BMY icon

Harfst & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Harfst & Associates’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100
Closed -$5K – 98
2017
Q2 		$5K Sell
100
-4,957
-98% -$270K ﹤0.01% 210
2017
Q1 		$275K Sell
5,057
-115
-2% -$6.31K 0.12% 53
2016
Q4 		$302K Buy
5,172
+244
+5% +$13.3K 0.15% 48
2016
Q3 		$265K Sell
4,928
-31,820
-87% -$2.04M 0.14% 57
2016
Q2 		$2.7M Buy
36,748
+32,536
+772% +$2.3M 1.09% 11
2016
Q1 		$269K Sell
4,212
-31,720
-88% -$2M 0.17% 58
2015
Q4 		$2.47M Buy
35,932
+30
+0.1% +$1.98K 1.01% 14
2015
Q3 		$2.13M Buy
35,902
+33,448
+1,363% +$2.12M 0.93% 16
2015
Q2 		$163K Buy
+2,454
New +$162K 0.09% 88

Other funds holding BMY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Harfst & Associates's BMY Position: Q3 2017 in Review

Harfst & Associates sold out of Bristol-Myers Squibb (BMY) in Q3 2017, closing a stake of 100 shares — an estimated $5K sold.

Harfst & Associates first reported a position in BMY in Q2 2015 and held it in 9 quarters. The position peaked at $2.7M in Q2 2016. 1,642 funds tracked by Wall St. Rank hold BMY as of Q3 2017.

  • Harfst & Associates reported no remaining Bristol-Myers Squibb position as of Q3 2017 after selling out during the quarter.
  • Harfst & Associates sold 100 Bristol-Myers Squibb shares in Q3 2017, an estimated $5K.
  • Harfst & Associates first reported a position in Bristol-Myers Squibb in Q2 2015 and held it in 9 quarters.
  • Harfst & Associates's Bristol-Myers Squibb position peaked at $2.7M in Q2 2016.
  • 1,642 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2017.

Based on Harfst & Associates's 13F filing for Q3 2017, filed 7 Nov 2017.